Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...

Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. Receive News & Ratings for Axsome ...

The agreement grants Hikma the right to market a generic version of Sunosi in the United States starting on or after September 1, 2040, if pediatric exclusivity is granted, or from March 1, 2040, ...

Under the terms of the settlement agreement, Axsome will grant Hikma a license to sell its generic version of Sunosi beginning on or after September 1, 2040, if pediatric exclusivity is granted ...

(RTTNews) - Axsome Therapeutics (AXSM) has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. resolving patent litigation related to Axsomes product Sunosi or solriamfetol.